Loading...
Header Logo
Keywords
Last Name
Institution

Connection

Search Results to

This is a "connection" page, showing the details of why an item matched the keywords from your search.


One or more keywords matched the following properties of Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.

PropertyValue
has major subject area list Benzoates; beta-Thalassemia; Deferoxamine; Iron Chelating Agents; Oxidants; Triazoles
information resource reference Walter PB, Macklin EA, Porter J, Evans P, Kwiatkowski JL, Neufeld EJ, Coates T, Giardina PJ, Vichinsky E, Olivieri N, Alberti D, Holland J, Harmatz P. Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica. 2008 Jun; 93(6):817-25.
label Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.

Search Criteria
  • beta Thalassemia